Patent intelligence · US
US 9254310
Therapeutic and cosmetic uses and applications of calreticulin
Therapeutic and cosmetic uses and applications of calreticulin
Patent details — US 9254310
- Jurisdiction
- US
- Status
- granted
- Grant date
- Feb 9, 2016
- Expiration
- Feb 4, 2036
- Applicant
- CALREGEN INC.
- Claims
- 15
- CPC classes
- A61K, A61K2800/91, A61K38/1738, A61K8/0208
Quick answer
US 9254310 (Therapeutic and cosmetic uses and applications of calreticulin) is held by CALREGEN INC.. Status: granted. Granted Feb 9, 2016. Expires Feb 4, 2036 (10 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- CALREGEN INC.
- Grant date
- Expiration
- Claims
- 15
- CPC classes
- A61K, A61K2800/91, A61K38/1738, A61K8/0208, A61K8/64, A61K8/735
More from CALREGEN INC.
Related pharmaceutical patents in our USPTO index.
-
US 12428463
Chimeric antigen receptors targeting abnormal glycobiology
granted -
US 12427148
Cancer treatment targeted to tumor adaptive responses to protein synthesis stress
granted -
US 12428416
ERK inhibitors and uses thereof
granted -
US 12427151
Compositions and method of treating cancer
granted -
US 12427197
Methods of producing cobalt nanoparticles and hollow metal nanospheres
granted -
US 12428489
Human PD-L2 antibodies and methods of use therefor
granted -
US 12427155
Treatment for tau-related diseases
granted -
US 12428455
Dominant negative CEBPB and CEBPD proteins and methods of use for decreasing viability of neoplastic cells
granted
Frequently asked questions
What is US patent 9254310?
US 9254310 (Therapeutic and cosmetic uses and applications of calreticulin) is held by CALREGEN INC.. Status: granted. Granted Feb 9, 2016. Expires Feb 4, 2036 (10 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 9254310?
CALREGEN INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 8,292 pharmaceutical patents for this assignee.
When does US 9254310 expire?
Our index shows an expiration date of Feb 4, 2036 (10 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.